Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Robert B Jenkins

Showing results (251-260 of 269) with videos related to

Pageof 27
Sort By:
Neuro-Oncology|August 21, 2018
Sex-specific gene and pathway modeling of inherited glioma riskQuinn T Ostrom, Warren Coleman, William Huang, et al.
Neuro-Oncology Advances|December 11, 2024
Establishment of a brain tumor consortium of Africa: Advancing collaborative research and advocacy for brain tumors in AfricaLateef A Odukoya, Kwadwo Darko, Francis Zerd, et al.
Journal of the National Cancer Institute|December 9, 2014
Germline mutations in shelterin complex genes are associated with familial gliomaMatthew N Bainbridge, Georgina N Armstrong, M Monica Gramatges, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|March 11, 2022
Temozolomide and Radiotherapy versus Radiotherapy Alone in Patients with Glioblastoma, IDH-wildtype: Post Hoc Analysis of the EORTC Randomized Phase III CATNON TrialC Mircea S Tesileanu, Marc Sanson, Wolfgang Wick, et al.
Cell Reports. Medicine|June 21, 2023
Haploinsufficiency of NFKBIA reshapes the epigenome antipodal to the IDH mutation and imparts disease fate in diffuse gliomasMarkus Bredel, Lluís Espinosa, Hyunsoo Kim, et al.
Scientific Reports|May 11, 2018
Sex-specific glioma genome-wide association study identifies new risk locus at 3p21.31 in females, and finds sex-differences in risk at 8q24.21Quinn T Ostrom, Ben Kinnersley, Margaret R Wrensch, et al.
Lancet (London, England)|August 13, 2017
Interim results from the CATNON trial (EORTC study 26053-22054) of treatment with concurrent and adjuvant temozolomide for 1p/19q non-co-deleted anaplastic glioma: a phase 3, randomised, open-label intergroup studyMartin J van den Bent, Brigitta Baumert, Sara C Erridge, et al.
The Lancet. Oncology|May 17, 2021
Adjuvant and concurrent temozolomide for 1p/19q non-co-deleted anaplastic glioma (CATNON; EORTC study 26053-22054): second interim analysis of a randomised, open-label, phase 3 studyMartin J van den Bent, C Mircea S Tesileanu, Wolfgang Wick, et al.
The Lancet. Oncology|December 25, 2025
Concurrent and adjuvant temozolomide for 1p/19q non-co-deleted anaplastic glioma (CATNON; EORTC study 26053-22054): final and exploratory analyses of a randomised, open-label, phase 3 trialMartin J van den Bent, Santoesha A Ghisai, Wolfgang Wick, et al.
Neuro-Oncology|April 29, 2021
Prognostic significance of genome-wide DNA methylation profiles within the randomized, phase 3, EORTC CATNON trial on non-1p/19q deleted anaplastic gliomaC Mircea S Tesileanu, Martin J van den Bent, Marc Sanson, et al.
Pageof 27

Showing results (251-260 of 269) with videos related to

Sort By:
Pageof 27
Neuro-Oncology|August 21, 2018
Sex-specific gene and pathway modeling of inherited glioma riskQuinn T Ostrom, Warren Coleman, William Huang, et al.
Neuro-Oncology Advances|December 11, 2024
Establishment of a brain tumor consortium of Africa: Advancing collaborative research and advocacy for brain tumors in AfricaLateef A Odukoya, Kwadwo Darko, Francis Zerd, et al.
Journal of the National Cancer Institute|December 9, 2014
Germline mutations in shelterin complex genes are associated with familial gliomaMatthew N Bainbridge, Georgina N Armstrong, M Monica Gramatges, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|March 11, 2022
Temozolomide and Radiotherapy versus Radiotherapy Alone in Patients with Glioblastoma, IDH-wildtype: Post Hoc Analysis of the EORTC Randomized Phase III CATNON TrialC Mircea S Tesileanu, Marc Sanson, Wolfgang Wick, et al.
Cell Reports. Medicine|June 21, 2023
Haploinsufficiency of NFKBIA reshapes the epigenome antipodal to the IDH mutation and imparts disease fate in diffuse gliomasMarkus Bredel, Lluís Espinosa, Hyunsoo Kim, et al.
Scientific Reports|May 11, 2018
Sex-specific glioma genome-wide association study identifies new risk locus at 3p21.31 in females, and finds sex-differences in risk at 8q24.21Quinn T Ostrom, Ben Kinnersley, Margaret R Wrensch, et al.
Lancet (London, England)|August 13, 2017
Interim results from the CATNON trial (EORTC study 26053-22054) of treatment with concurrent and adjuvant temozolomide for 1p/19q non-co-deleted anaplastic glioma: a phase 3, randomised, open-label intergroup studyMartin J van den Bent, Brigitta Baumert, Sara C Erridge, et al.
The Lancet. Oncology|May 17, 2021
Adjuvant and concurrent temozolomide for 1p/19q non-co-deleted anaplastic glioma (CATNON; EORTC study 26053-22054): second interim analysis of a randomised, open-label, phase 3 studyMartin J van den Bent, C Mircea S Tesileanu, Wolfgang Wick, et al.
The Lancet. Oncology|December 25, 2025
Concurrent and adjuvant temozolomide for 1p/19q non-co-deleted anaplastic glioma (CATNON; EORTC study 26053-22054): final and exploratory analyses of a randomised, open-label, phase 3 trialMartin J van den Bent, Santoesha A Ghisai, Wolfgang Wick, et al.
Neuro-Oncology|April 29, 2021
Prognostic significance of genome-wide DNA methylation profiles within the randomized, phase 3, EORTC CATNON trial on non-1p/19q deleted anaplastic gliomaC Mircea S Tesileanu, Martin J van den Bent, Marc Sanson, et al.
Pageof 27